Basics Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat. IPO Date: July 31, 1996 Sector: Healthcare Industry: Biotech Market Cap: $893.22M Activated in VL: True Average Daily Range Avg Daily Range: $0.11 | 2.89% Avg Daily Range (30 D): $0.04 | 3.07% Avg Daily Range (90 D): $0.05 | 3.38% Institutional Daily Volume Avg Daily Volume: 2.79M Avg Daily Volume (30 D): 8.97M Avg Daily Volume (90 D): 9.14M Trade Size Avg Trade Size (Sh.): 345 Avg Trade Size (Sh.) (30 D): 537 Avg Trade Size (Sh.) (90 D): 491 Institutional Trades Total Inst.Trades: 2,695 Avg Inst. Trade: $1.85M Avg Inst. Trade (30 D): $.93M Avg Inst. Trade (90 D): $1.12M Avg Inst. Trade Volume: .61M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.32M Avg Closing Trade (30 D): $.87M Avg Closing Trade (90 D): $1.18M Avg Closing Volume: 808.25K     News Aug 19, 2025 @ 12:00 PM SpyGlass Pharma Appoints Elizabeth O’Farrel... Source: Patrick Mooney Aug 13, 2025 @ 11:52 PM GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is... Source: Bragar Eagel & Squire, P.C. May 12, 2025 @ 1:54 PM GERN Investors are Reminded of an Opportunity to L... Source: Prnewswire May 11, 2025 @ 12:17 PM Faruqi & Faruqi Reminds Geron Investors of the Pen... Source: N/A May 9, 2025 @ 1:00 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: Pomerantz Llp Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.13 $-.02 $-.03 Diluted EPS $-.13 $-.02 $-.03 Revenue $ 164.45M $ 49.04M $ 39.6M Gross Profit $ $ $ Net Income / Loss $ -88.01M $ -16.38M $ -19.84M Operating Income / Loss $ -77.42M $ -12.45M $ -16.7M Cost of Revenue $ $ $ Net Cash Flow $ -38.45M $ -6.01M $ 4.73M PE Ratio